Metabolic syndrome in patients with peripheral arterial disease

Estirado, Eva; Lahoz, Carlos; Laguna, Fernando Ballester; García-Iglesias, Francisca; González-Alegre, M.T.; Mostaza, José María

doi:10.1016/j.rceng.2014.05.006

Cited by 4 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors demonstrated that the prevalence of MetS in PA D patients is high (63%) and is independent of the evolution time of PAD. According to our experience we are agree with Estirado et al 18 ; we believe that PA D (documented using ABI <0.9, lower limb amputation due to chronic ischemia or prior revascularization in the lower limbs), can be presented in MetS patients and that it is a validated marker of subclinical atherosclerosis and a predictor of CV events, like an increased carotid IMT.…”

Section: Metabolic Syndrome and Peripheral Arterial Disease Síndrome supporting

confidence: 91%

“…These studies demonstrated that the prevalence of MetS is higher in patients with PA D but their limits were that the patients often exhibited clinical manifestations of arteriosclerosis in other vascular territories. 14---17 In this regard the objective of the study presented in this issue of Rev Clin Esp by Estirado et al 18 is to assess the prevalence of MetS in patients with PA D but without known atherosclerosis in other districts. The authors demonstrated that the prevalence of MetS in PA D patients is high (63%) and is independent of the evolution time of PAD.…”

Section: Metabolic Syndrome and Peripheral Arterial Disease Síndrome mentioning

confidence: 99%

See 1 more Smart Citation

Metabolic syndrome and peripheral arterial disease

Novo¹,

Paleologo²

2014

Revista Clínica Española

View full text Add to dashboard Cite

Section: Metabolic Syndrome and Peripheral Arterial Disease Síndrome supporting

confidence: 91%

Section: Metabolic Syndrome and Peripheral Arterial Disease Síndrome mentioning

confidence: 99%

Metabolic syndrome and peripheral arterial disease

Novo¹,

Paleologo²

2014

Revista Clínica Española

View full text Add to dashboard Cite

“…Si bien el síndrome metabólico y la resistencia insulínica podrían favorecer la aparición de EAP al facilitar el desarrollo de la arteriosclerosis, también sería posible que los pacientes con EAP desarrollaran con más frecuencia síndrome metabólico como consecuencia de una disminución (37) mantenida en su nivel de actividad física .…”

Section: Discussionunclassified

Peripheral arterial disease determined by the ankle-brachial index in patients with metabolic syndrome

Pineda

Aparicio

Santander

et al. 2018

Rev. virtual Soc. Parag. Med. Int

View full text Add to dashboard Cite

Introducción: el síndrome metabólico se asocia con un mayor riesgo cardiovascular, incluyendo la enfermedad arterial periférica. Objetivos: determinar la frecuencia de la enfermedad arterial periférica detectada por el método índice tobillo brazo en pacientes con síndrome metabólico, describir las características clínicas y laboratoriales del síndrome metabólico y detallar la sintomatología de los pacientes con EAP según la escala de Fontaine Metodología: estudio observacional prospectivo realizado en 100 pacientes adultos que cumplían con criterios para síndrome metabólico, según los criterios armonizados del año 2009 internados en el Servicio de Clínica Médica del Hospital Nacional (Itauguá, Paraguay) en años 2016 y 2017. El índice tobillo-brazo derecho se calculó por el cociente de la presión arterial sistólica del tobillo derecho dividido la presión arterial sistólica más elevada de cualquier brazo y de forma similar para el índice tobillo-brazo izquierdo. Se consideró índice tobillo-brazo compatible con enfermedad arterial periférica todo valor ≤ 0,9. Resultados: se hallo 23% de insuficiencia vascular periférica, siendo 18% del lado derecho, 13% del lado izquierdo y 8% bilateral. Los criterios para síndrome metabólico fueron: hipertensión arterial (100%), circunferencia abdominal aumentada (89%), glicemia en ayunas elevada o diabetes mellitus tipo 2 (50%), colesterol HDL bajo (47%), triglicéridos elevados (35%). Solo 7/23 (30%) sujetos presentaron síntomas según la escala de Fontaine, 5 pacientes en estadio IIa y 2 en estadio IIb. Conclusión: la frecuencia de enfermedad arterial periférica fue 23%. La claudicación de miembros estaba presente en 30% de los afectados.

show abstract

Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain

et al. 2015

View full text Add to dashboard Cite

IntroductionCardiovascular diseases (CVDs) represent a major Public Health burden. High serum cholesterol levels have been linked to major CV risk. The objectives of this study were to review the epidemiology of hypercholesterolemia in high risk CV patients from Spain, by assessing its prevalence, the proportion of diagnosed patients undergoing pharmacological treatment and the degree of attained lipid control.MethodsA systematic literature review was carried out using Medline and two Spanish databases. Manuscripts containing information on hypercholesterolemia in several high CV risk groups [diabetes mellitus (DM), Systematic COronary Risk Evaluation (SCORE) risk >5, or documented CVD], published between January 2010 and October 2014, were included.ResultsOf the 1947 published references initially retrieved, a full-text review was done on 264 manuscripts and 120 were finally included. Prevalence of hypercholesterolemia ranged from 50 to 84% in diabetics, 30–60% in patients with DM or elevated SCORE risk, 64–74% with coronary heart disease, 40–70% in stroke patients, and 60–80% in those with peripheral artery disease. Despite the finding that most of them were on pharmacological treatment, acceptable control of serum lipids was very variable, ranging from 15% to 65%. Among those with heterozygous familial hypercholesterolemia, 95–100% received treatment but less than 50% achieved their therapeutic goals.ConclusionsAn elevated prevalence of hypercholesterolemia can be found in targeted groups at high CV risk. Although most patients are receiving pharmacological treatment, rates of lipid control continue to be low, both in primary and secondary prevention.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-015-0252-y) contains supplementary material, which is available to authorized users.

show abstract

Metabolic syndrome in patients with peripheral arterial disease

Cited by 4 publications

References 29 publications

Metabolic syndrome and peripheral arterial disease

Metabolic syndrome and peripheral arterial disease

Peripheral arterial disease determined by the ankle-brachial index in patients with metabolic syndrome

Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain

Contact Info

Product

Resources

About